Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone
8/8/2012 10:28:47 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, announced today that Kyowa Hakko Kirin Co., Ltd. (TSE: 4151) (KHK) has recognized the successful achievement of an in vivo activity milestone in the development of its second collaborative therapeutic oncology candidate. This achievement triggers an undisclosed milestone payment to Dicerna.
comments powered by